- £715.57m
- £721.29m
- £270.04m
- 73
- 18
- 94
- 69
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 25.07 | ||
| PEG Ratio (f) | 1.16 | ||
| EPS Growth (f) | 27.66% | ||
| Dividend Yield (f) | 1.24% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.51 | ||
| Price to Tang. Book | 21.74 | ||
| Price to Free Cashflow | 18.83 | ||
| Price to Sales | 2.65 | ||
| EV to EBITDA | 20.84 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.85% | ||
| Return on Equity | 14.4% | ||
| Operating Margin | 9.67% | ||
Financial Summary
| Year End 30th Apr | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 143.31 | 137.76 | 182.71 | 202.53 | 270.04 | 291.68 | 313.73 | 15.56% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -40.46 | +87.72 | +16.62 | +35.4 | +17.31 | +34.24 | +12 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cohort plc is the parent company of seven businesses based in the United Kingdom, Australia, Germany and Portugal, providing a range of services and products for domestic and export customers in defense and related markets. The Company’s segments include Communications and Intelligence, and Sensors and Effectors. Communications and Intelligence segment includes EID, EM Solutions, MASS and MCL; and Sensors and Effectors segment includes Chess, ELAC SONAR and SEA. EID designs and manufactures advanced communications systems for naval and military customers. EM Solutions designs, assembles, tests, and supports satellite communications on-the-move terminals. MASS is a specialist data technology company. MCL designs, sources and supports advanced electronic and surveillance technology. Chess Dynamics offers surveillance, tracking and fire-control systems. ELAC SONAR supplies advanced sonar systems and underwater communications. SEA delivers and supports technology-based products.
Directors
- Nicholas Prest NEC
- Andrew Thomis CEO
- Simon Walther FID
- Raquel McGrath GCN
- Richard Flitton MDR
- Frederico Lemos MDR
- Ole Schneider MDR
- Chris Stanley MDR
- Bernd Szukay MDR
- David Tuddenham MDR
- Shane Knight OTH
- Stanley Carter NED
- Edward Lowe NID
- Beatrice Nicholas NID (61)
- Jeffrey Perrin NID (70)
- Last Annual
- April 30th, 2025
- Last Interim
- April 30th, 2025
- Incorporated
- January 23rd, 2006
- Public Since
- March 8th, 2006
- No. of Employees
- 1,309
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
London Stock Exchange- Shares in Issue
- 46,708,457
- Address
- Arlington Business Park, Theale, READING, RG7 4SW
- Web
- https://www.cohortplc.com/
- Phone
- +44 1189090390
- Contact
- Raquel Mcgrath
- Auditors
- RSM UK Audit LLP
Latest News for CHRT
Upcoming Events for CHRT
Dividend For CHRT.L - 11.0500 GBX
Cohort PLC Annual Shareholders Meeting
Half Year 2026 Cohort PLC Earnings Release
Similar to CHRT
1Spatial
London Stock Exchange
accesso Technology
London Stock Exchange
Activeops
London Stock Exchange
Acuity RM
London Stock Exchange
AdvancedAdvT
London Stock Exchange
FAQ
As of Today at 20:00 UTC, shares in Cohort are trading at 1,532.00p. This share price information is delayed by 15 minutes.
Shares in Cohort last closed at 1,532.00p and the price had moved by +79.39% over the past 365 days. In terms of relative price strength the Cohort share price has outperformed the FTSE All Share Index by +64.42% over the past year.
The overall consensus recommendation for Cohort is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Cohort dividend yield is 1.06% based on the trailing twelve month period.
Last year, Cohort paid a total dividend of £0.16, and it currently has a trailing dividend yield of 1.06%.Looking ahead, shares in Cohort are due to go ex-dividend on 2025-08-21 and the next dividend pay date is 2025-10-03.
Cohort are due to go ex-dividend on 2025-08-21 and the next dividend pay date is 2025-10-03. The historic dividend yield on Cohort shares is currently 1.06%.
To buy shares in Cohort you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 1,532.00p, shares in Cohort had a market capitalisation of £715.57m.
Here are the trading details for Cohort:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: CHRT
Based on an overall assessment of its quality, value and momentum Cohort is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cohort is 1,506.67p. That is 1.65% below the last closing price of 1,532.00p.
Analysts covering Cohort currently have a consensus Earnings Per Share (EPS) forecast of £0.59 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cohort. Over the past six months, its share price has outperformed the FTSE All Share Index by +22.95%.
As of the last closing price of 1,532.00p, shares in Cohort were trading +25.52% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cohort PE ratio based on its reported earnings over the past 12 months is 25.07. The shares last closed at 1,532.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cohort's management team is headed by:
- Nicholas Prest - NEC
- Andrew Thomis - CEO
- Simon Walther - FID
- Raquel McGrath - GCN
- Richard Flitton - MDR
- Frederico Lemos - MDR
- Ole Schneider - MDR
- Chris Stanley - MDR
- Bernd Szukay - MDR
- David Tuddenham - MDR
- Shane Knight - OTH
- Stanley Carter - NED
- Edward Lowe - NID
- Beatrice Nicholas - NID
- Jeffrey Perrin - NID